• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


             

New Enrollment PAS Registry


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Progress Inadequate
Application Number P170003 / PAS002
Date Current Protocol Accepted 11/26/2019
Study Name New Enrollment PAS Registry
General Study Protocol Parameters
Study Design Active Surveillance
Data Source Sponsor Registry
Comparison Group Objective Performance Criterion
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description To demonstrate safety and assess the clinical use and outcomes of the Lutonix DCB for treatment of dysfunctional AV fistulae located in the arm in a heterogeneous patient population in a real world clinical practice.



A prospective, global multicenter, single arm, post-approval registry study of newly enrolled patients.

Study Population Description Subjects presenting with clinical and hemodynamic abnormalities in arteriovenous fistulae located in the arm who meet all inclusion criteria and none of the exclusion criteria.
Sample Size A total of 213 subjects will be enrolled at a minimum of 15 and a maximum of 30 U.S. and International sites. Approximately 50% of subjects enrolled and study sites will be from the U.S.

Based on a TLPP rate of 71.4%, a non-inferiority margin of 10%, a 10% drop-out rate and one-sided exact binomial test p = 0.05, sample size of 213 provide 90% power for evaluating the primary effectiveness hypothesis comparing 61.4% PG.



Based a primary safety endpoint rate of 95% (pivotal trial), a non-inferiority margin of 6%, and one-sided exact binomial test p = 0.05, sample size of 213 will provide 95% power evaluating the primary safety hypothesis comparing to 89% PG.

Data Collection Primary Safety Endpoint:

Freedom from any serious adverse event(s) involving the AV access circuit through 30 days



Primary Effectiveness Endpoint:

TLPP through 6 months

defined as the interval following index procedure until clinically-driven reintervention of the target lesion or access thrombosis, through 6 months



Secondary Safety Endpoints:

1. Freedom from any serious adverse event(s) involving the AV access circuit through 6, 12, 18 and 24 months

2. Rate of device and procedure related adverse events assessed at 6, 12, 18 and 24 months



Secondary Effectiveness Endpoints:



1. TLPP evaluated at 12, 18 and 24 months

2. Number of reinterventions to maintain target lesion patency at 6, 12, 18 and 24 months

3. Time to loss of Target Lesion Primary Patency (i.e. time between index procedure to the first loss of patency)

4. Access Circuit Primary Patency (ACPP) evaluated at 6, 12, 18 and 24 months

5. Number of reinterventions to maintain access circuit patency at 6, 12, 18 and 24 months

6. Device, Procedural and Clinical Success

7. Abandonment of permanent access in the index extremity at 6, 12, 18 and 24 months

8. Secondary Patency of the Access Circuit at 6, 12, 18 and 24 months

9. Time to loss of target lesion secondary patency following DCB (i.e. time between first reintervention with a DCB to the next loss of patency)

Follow-up Visits and Length of Follow-up 24 months


New Enrollment PAS Registry Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
six month report 02/23/2018 03/01/2018 Overdue/Received
one year report 08/25/2018 08/22/2018 On Time
18 month report 02/23/2019 02/22/2019 On Time
two year report 08/25/2019 08/19/2019 On Time
three year report 08/24/2020    
four year report 08/24/2021    
Final report 02/25/2022    


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Related Links

-
-